The COVID-19 virus that can cause severe respiratory complication has already infected more than 197,384, and killed more 7,962 people worldwide.1 A key step to help address this urgent public health situation is the ability to quickly and accurately diagnose infected individuals to mitigate the spread of the virus.
As part of Singapore’s unwavering effort in curbing the widespread deadly COVID-19, A*STAR Fortitude Kit 2.0 is the first RT-PCR SARS-CoV-2 diagnostic test in Singapore that has been deployed as complete kits to the clinical community. It was developed by researchers at Singapore’s Agency for Science, Technology and Research (A*STAR) and Tan Tock Seng Hospital (TTSH). The kit has been given Provisional Authorisation from the Health Sciences Authority (HSA), Singapore, for their intended use in Singapore.
Fortitude Kit 2.0 has been swiftly dispatched to both the Singapore public hospital networks as well as China to accurately screen thousands of patients for the coronavirus, reducing the wait time for results and allowing those infected to be treated timely.
Join this webinar to find out more on the recipe of success of the Singapore team in producing the Fortitude Kit 2.0 with high accuracy and performance within a short period of time, how the kit works and how RT-PCR enables SARS-CoV-2 detection.
Dr Ruifen WENG is the DxD Hub Project Lead for the A*STAR Fortitude Kit 2.0. As a national initiative led by A*STAR’s commercialisation arm, A*ccelerate, the DxD Hub focuses on the development and productisation of diagnostic solutions. The output of the DxD Hub development projects are commercial products ready for clinical adoption. Dr Weng manages the productisation of a portfolio of projects ranging from molecular diagnostics to immunoassays to cytopathology- & histopathology based medical devices. Dr Weng obtained her PhD in Life Sciences from the National University of Singapore in 2013.
Angela is a Sr. Product Manager for the Life Science Group at Bio-Rad currently managing amplification consumables including PCR and qPCR reagents. She has over 15 years of biotech industry experience in product life cycle management, new product development, and marketing. She recently drove the commercialization of a new one-step RT-qPCR reagent designed for virus/pathogen detection, Reliance One-Step Multiplex Supermix.
1Data correct as of March 18th, 6PM GMT+8 2020.